Home › Research › Biomarkers
Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings
Huber H, Blennow K, Zetterberg H, Boada M, Jeromin A, Weninger H, Nuñez-Llaves R, Aguilera N et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024-01-29
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Background We aimed to evaluate the precision of Alzheimer's disease (AD) and neurodegeneration biomarker measurements from venous dried plasma spots (DPS v enous ) for the diagnosis and monitoring of neurodegenerative diseases in remote settings. Methods In a discovery (n = 154) and a validation cohort (n = 115), glial fibrillary acidic protein (GFAP); neurofilament light (NfL); amyloid beta (Aβ) 40, Aβ42; and phosphorylated tau (p-tau181 and p-tau217) were measured in paired DPS venous and ethylenediaminetetraacetic acid plasma samples with single-molecule array. In the validation cohort, a subset of participants (n = 99) had cerebrospinal fluid (CSF) biomarkers. Results All DPS venous and plasma analytes correlated significantly, except for Aβ42. In the validation cohort, DPS venous GFAP, NfL, p-tau181, and p-tau217 differed between CSF Aβ-positive and -negative individuals and were associated with worsening cognition. Discussion Our data suggest that measuring blood biomarkers related to AD pathology and neurodegeneration from DPS venous extends the utility of blood-based biomarkers to remote settings with simplified sampling conditions, storage, and logistics. Highlights A wide array of biomarkers related to Alzheimer's disease (AD) and neurodegeneration were detectable in dried plasma spots (DPS venous ). DPS venous biomarkers correlated with standard procedures and cognitive status. DPS venous biomarkers had a good diagnostic accuracy discriminating amyloid status. Our findings show the potential interchangeability of DPS venous and plasma sampling. DPS venous may facilitate remote and temperature-independent sampling for AD biomarker measurement. Innovative tools for blood biomarker sampling may help recognizing the earliest changes of AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Huber, H., Blennow, K., Zetterberg, H., Boada, M., Jeromin, A., Weninger, H., et al. (2024). Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.13697
Vancouver
Huber H, Blennow K, Zetterberg H, Boada M, Jeromin A, Weninger H, et al. Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. doi:10.1002/alz.13697. PMID: 38284555.
BibTeX
@article{huber2024-38284555,
author = {Huber, H. and Blennow, K. and Zetterberg, H. and Boada, M. and Jeromin, A. and Weninger, H. and Nuñez-Llaves, R. and Aguilera, N. and others},
title = {{Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2024},
doi = {10.1002/alz.13697},
pmid = {38284555},
url = {https://doi.org/10.1002/alz.13697}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results All DPS venous and plasma analytes correlated significantly, except for Aβ42.
- In the validation cohort, DPS venous GFAP, NfL, p-tau181, and p-tau217 differed between CSF Aβ-positive and -negative individuals and were associated with worsening cognition.
- Discussion Our data suggest that measuring blood biomarkers related to AD pathology and neurodegeneration from DPS venous extends the utility of blood-based biomarkers to remote settings with simplified sampling conditions, storage, and logistics.
- Our findings show the potential interchangeability of DPS venous and plasma sampling.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants154
- Evidence strengthModerate
How this study scored 60/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 35 of the 58 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 154 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38284555) |
| Free to read | 2 / 2 | Free to read |
| Points | 35 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 35 of the 58 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.